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ABSTRACT
Protamine is a natural cationic peptide mixture used as a drug for the neutralization of heparin and in
formulations of slow-release insulin. In addition, Protamine can be used for the stabilization and deliv-
ery of nucleic acids (antisense, small interfering RNA (siRNA), immunostimulatory nucleic acids, plasmid
DNA, or messenger RNA) and is therefore included in several compositions that are in clinical develop-
ment. Notably, when mixed with RNA, protamine spontaneously generates particles in the size range
of 20–1000 nm depending on the formulation conditions (concentration of the reagents, ratio, and
presence of salts). These particles are being used for vaccination and immuno-stimulation. Several
grades of protamine are available, and we compared them in the context of complex formation with
messenger RNA (mRNA). We found that the different available protamine preparations largely vary in
their composition and capacity to transfect mRNA. Our data point to the source of protamine as an
important parameter for the production of therapeutic protamine-based complexes.
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Protamine is a conserved natural cationic peptide mixture
that condenses sperm DNA in all vertebrates (Balhorn, 2007).
Unrelated to its physiological role, protamine is used as a
drug to inhibit heparin after surgery (Jaques, 1973). It is also
the moiety that mediates slow release in intermediate-acting
insulin formulations. In addition, protamine has been
reported to enhance the transfection of RNA in cultured cells
(Amos, 1961; Amos and Kearns, 1963; Billiau et al., 1969) and
is still intensively used to deliver different types of RNA
in vitro and in vivo (Amos, 1961; Amos and Kearns, 1963; Choi
et al., 2010; Bell et al., 2018; Sato et al., 2018; Shi et al., 2019).
Indeed, protamine spontaneously associates with purified,
recombinant, or chemically synthesized nucleic acids and
forms complexes (Amos and Kearns, 1963; Billiau et al., 1969;
Hoerr et al., 2000; Scheel et al., 2004; Scheel et al., 2005;
Scheel et al., 2006). We showed that nanoparticles of a
defined size ranging from 20nm to more than 1000 nm can
be easily obtained by simply adjusting the concentration, for-
mulation, and ratio of RNA and protamine (Rettig et al., 2010;
Tusup and Pascolo, 2017). Such protamine-based nanopar-
ticles (also termed proticles) are broadly used to deliver oligo-
nucleotides (antisense, small interfering RNA (siRNA), and
immunostimulatory nucleic acids; reviewed by Scheicher et al.
(2015)) as well as encoding nucleic acids (plasmid DNA (Vighi
et al., 2012) or messenger RNA (mRNA) (Hoerr et al., 2000;
Scheel et al., 2004; Scheel et al., 2005; Scheel et al., 2006;
Weide et al., 2009; Parvanova et al., 2011); reviewed by
Kauffman et al. (2016)). Furthermore, complexing protamine
with antibodies offers a platform to associate RNA and anti-
bodies (Baumer et al., 2016; Baumer et al., 2015; Song et al.,
2005). Because of the crucial role this component plays in
drug development, we aimed to compare different sources of
protamine. Indeed, it is available in hydrochloric or sulfated
forms and originates from herring or salmon. In addition, as a
biochemical product, protamine is available in different purity
grades. The impact of the origin of protamine on particle for-
mation and functionality has not been explored. We report
here that although all protamine sources can form similar
homogenous nanoparticles when mixed with RNA, and pro-
duce immunostimulatory complexes, the pharmaceutical
grade chloride protamine used for heparin neutralization is
the best for obtaining the expression of condensed mRNA.
2. Materials and methods
2.1. mRNA
mRNAs were produced using in vitro transcription at the ‘ivt
mRNA production and formulation platform’ in Z€urich
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The 50 end consisted of a CleanCapTM (Trilink) followed by an
eIF4G aptamer as the 50 untranslated region (Tusup and
Pascolo, 2018) and by a codon-optimized firefly luciferase
open reading frame. The 30 end consisted of a tandem
repeat of the mouse beta-globin 30 UTR and a poly-A tail
(Tusup et al., 2019). The transcription was made in the pres-
ence of the four canonical bases (alanine(A), cysteine (C), gly-
cine (G) , and uracil (U)) to obtain immunostimulatory RNA
and in the presence of pseudo-uridine instead of uridine to
obtain immuno-silent mRNA used for luciferase expression
assays. RNA was diluted in RNase-free water, and the concen-
tration measured using a nanodrop was adjusted to 1mg/ml.
The quality and integrity of ivt mRNAs were checked using
agarose gel electrophoresis. The RNAs were stored at 20 C.
2.2. Protamines
We compared the performance of eight commercially avail-
able protamines: clinical protamine Ipex 5000 IU (MEDA) that
is a solution, and seven Sigma-Aldrich products in powders:
protamine grade II–V, protamine grade X, protamine meeting
USP standards (Sigma-Aldrich, St. Louis, MO) and protamine
for biochemistry. The protamine sources and formulations
are shown in Table 1.
All protamines were diluted in pure water to a concentra-
tion of 1mg/ml and stored at 4 C.
2.3. Sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE)
SDS-PAGE was carried out using 5–20% polyacrylamide gels.
Five micrograms of each Protamine type solution was mixed
with 2x NuPAGE LDS sample buffer (Invitrogen, Carlsbad,
MA) and 1M dithiothreitol (DTT) solution at a ratio of 5:4:1
(sample in water:LDS:DTT). Samples were loaded on the gel
and subjected to electrophoresis. After being separated, the
proteins were visualized by staining with GelCodeTM blue
safe protein stain (Thermo Fisher Scientific, Waltham, MA).
2.4. Preparation and physical analysis of protamine-
RNA particles
Preparation of the proticles was performed as described pre-
viously (Tusup and Pascolo, 2017). In brief, protamine
(0.75mg/ml) was mixed with mRNA (0.25mg/mL) in equal
volumes to obtain a ratio of 3:1 (protamine:mRNA w/w) and
left for 10min at room temperature. One milliliter of 5%
glucose solution in pure water was added, and the size dis-
tribution of the protamine-mRNA complexes was character-
ized by dynamic light scattering with a ZetaSizer 3000HSA
(Malvern Instruments, Worcestershire, UK). Data were ana-
lyzed with the built-in DTS software (Raleigh, NC).
2.5. Cells and transfections
Human embryonic kidney (HEK) cells were maintained in
Roswell Park Memorial Institute (RPMI) medium (Thermo
Fisher Scientific) containing 10% fetal calf serum (FCS),
200mM L-glutamine (Gibco, Carlsbad, CA) and 0.2% anti-
microbial reagent Normocin (InvivoGen, San Diego, CA). For
Luciferase experiments, the transfection of tumor cells was
performed with 100,000 tumor cells per well in 100ll of
RPMI medium supplemented with 10% FCS, 200mM L-glu-
tamine (Gibco) and 0.2% antimicrobial reagent Normocin
(InvivoGen) by adding the mixture of RNA and protamine to
obtain 1mg of mRNA per well. The luciferase activity was
recorded one day after transfection by adding 25 ll of
Bright-Glo luciferase assay solution (Promega, Madison, WA)
and measuring the activity using GloMax luminometer equip-
ment (Promega).
2.6. Immuno-stimulation
Human PBMCs were isolated from the blood of healthy
donors by using Ficoll-PaqueTM Plus (GE Healthcare Life
Sciences, Chicago, IL). A total of 100,000 cells per well were
plated on 96-well plates and incubated with protamine-
mRNA nanoparticles overnight. After that time, supernatants
were taken, and interferon alpha (IFN-a) concentration was
measured via enzyme-linked immunosorbent assay (ELISA)
by following the manufacturer’s protocol (Human IFN-a pan
ELISA development kit, MABTECH, Sweden). The absorbance
was measured on an ELISA reader (BioTek, ELx808
Absorbance Reader, software Gen 5, v2.07 version,
Winooski, VT).
2.7. Fractionation of clinical protamine
Clinical protamine (2.5ml at 50mg/ml) was fractionated with
a PD-10 desalting column (GE Healthcare) using a gravity
protocol and pure water for elution. Twenty-four fractions
were collected and visualized with SDS-PAGE. Subsequently,
the protein concentration of all samples was measured with
a BCA assay (Thermo ScientificTM PierceTM BCATM Protein
Assay). The protein concentration in all fractions was
adjusted to 90 mg/ml, and the fractions were mixed with
mRNA at a ratio of 3:1 (protamine:RNA, w/w). The transfec-
tion efficiency was measured in HEK cells by luciferase assay,
as described above.
3. Results and discussion
The commercially available protamines (clinical and research
grades) were checked for their peptide composition using
electrophoresis on SDS-PAGE gels, as shown in Figure 1. Two
Table 1. Formulations and sources of protamines used in this article.
Protamine type Source Salt
Clinical 5000 Salmon Chloride
Grade II Salmon Sulfate
Grade III Herring Sulfate
Grade IV Salmon Not indicated
Grade V Salmon Chloride
Grade X Salmon Sulfate
Grade USP Salmon Sulfate
Grade for Biochemistry Not indicated Sulfate
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distinct profiles were obtained: (i) a smear of strongly stained
small peptides for clinical hydrochloride protamine and
Sigma grades IV and V, and (ii) a few defined weakly stained
single bands for Sigma grades II, III X, USP, and BC (in each
lane there are 5 lg of protein). The differences in staining
patterns and intensities correlated with the counter ion:
chloride protamines (Clinical and Grade V) gave the strongly
stained smear while sulfate protamines (Grade II, III, X, USP,
and BC) gave the weakly stained bands. A direct comparison
between clinical grade sulfate and chloride protamines
showed that indeed the chloride protamine gives a stronger
staining than the sulfate protamine (Supplementary Figure
1). In line with this observation, Benayahu and Aronson
(1983) reported different behaviors of chloride and sulfate
protamines that could be actually attributed more to the dif-
ferent manufacturing procedure involved in their preparation
than to the counterion itself. There was no correlation
between the protamine source and its appearance on the
SDS-PAGE gel. Thus, several physically distinct products are
sold as protamines and these differences prompted us to
check their functionality.
First, their capacity to generate nanoparticles when mixed
with mRNA in conditions suitable to generate less than
200 nm complexes was evaluated. At this stage, by compar-
ing the concentrations of clinical protamine to those of
Sigma protamines, we found that the concentration of clin-
ical protamine is three-fold greater than previously reported
(Tusup and Pascolo, 2017). This is due to the fact that the
BSA used as a standard in BCA assays has an amino acid
composition that is not similar to that of arginine-rich pro-
tamine. When BSA standard curves are used, the clinical pro-
tamine 5000 has an apparent concentration of 14mg/ml. We
used to dilute it 14 times to obtain a 1mg/ml solution
(Tusup and Pascolo, 2017). However, when the Sigma pro-
tamine powder is dissolved at 1mg/ml and used as a stand-
ard in the BCA assay, the clinical protamine 5000 appears to
have a concentration of 50mg/ml (Supplementary Figure 2).
Thus, the protamine-to-RNA mass ratio that we used in the
past to generate nanoparticles was not 1:1 but 3:1.
In light of the new quantification results, we now use a
50-fold dilution of clinical chloride Protamine 5000 to get a
concentration of 1mg/ml and from this solution, we use a
Protamine-to-RNA mass ratio of 3:1. Under these conditions,
all tested protamines except grade IV could generate nano-
particles of the expected average size close to 100 nm
(Figure 2). As the salt of grade IV is not indicated in its docu-
mentation, we postulate that this preparation contains a
high salt concentration, which results in increased particle
sizes when it is mixed with RNA (Rettig et al., 2010).
We have shown that protamine-RNA nanoparticles are
immunostimulatory, as they can trigger RNA sensors in endo-
somes (e.g. toll-like receptors (TLR)- 7 and 8) (Scheel et al.,
2006; Scheel et al., 2004; Scheel et al., 2005; Rettig et al.,
2010). We also reported previously that the size of the par-
ticles affects the type of immuno-stimulation: small particles
activate TLR7-expressing IFN-a-producing plasmacytoid
Figure 1. SDS-PAGE analysis. Each protamine formulation was mixed with loading buffer and 5 lg of the sample was run on the gel, which was then stained. The
labels indicate the location of bands from a protein marker.
Figure 2. Average size of the protamine-RNA nanoparticles. Protamine and
RNA were mixed as specified in the section ‘Materials and Methods’ and the
particles were analyzed on a ZetaSizer. The data represent triplicate mean val-
ues; error bars: SD; d is ‘diameter.’
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dendritic cells, whereas large particles activate TLR8-express-
ing monocytes that produce inflammatory cytokines such as
TNF-a (Rettig et al., 2010). Here, as we focused on particles
smaller than 200 nm, we measured IFN-a production in cul-
tured human PBMCs. When mixed with RNA, all commercially
available protamines tested here generated similar innate
immune responses in PBMCs (Figure 3). Thus, independent
of their origin, salt and appearance on SDS-PAGE, protamines
when mixed with RNA can generate nanoparticles that can
spontaneously home to endosomes and stimulate TLRs,
allowing the production of type I interferon by immune cells.
Finally, the cytosolic delivery capacity of all protamines
was tested. To this end, we measured the translation of
mRNA. Surprisingly, only the clinical chloride protamine 5000
produced a strong expression of the condensed mRNA at
the 3:1 ratio (Figure 4). Increasing the protamine to RNA ratio
could improve the transfection capacities of other
protamines (Supplementary Figure 3). However, most prot-
amines were relatively inefficient at all ratios (grade IV giving
barely any detectable luciferase activity), while clinical chlor-
ide protamine 5000 remained the most efficacious one. This
feature might be attributed to several functional characteris-
tics of clinical chloride protamine 5000 such as the capacity
to protect mRNA from degradation, to facilitate cellular
uptake, to induce endosomal escape, or to enable mRNA dis-
sociation from proticles when within the cytosol. Further
mechanistic studies will be required to analyze those aspects
in details. Meanwhile, to further characterize the type of
protamines that allow transfection, we fractionated clinical
chloride protamine 5000 on Sephadex P25 columns (Figure
5(A)) and tested the fractions in the mRNA transfection assay
(Figure 5(B)). It appears that the large protamines contain
the moieties that are critical to drive the expression of the
condensed mRNA: fraction 5, which contains only the high-
est weight protamine, produced the best transfection result.
This protamine results in expression levels more than two-
fold higher than that observed with the full mixture of clin-
ical chloride protamine peptides. Thus, new preparations of
protamines that contain only the largest peptides may be
optimal for the cytosolic delivery of RNA.
Figure 5. Fractionation of clinical protamine. (A) Visualization of the clinical
protamine fractions on polyacrylamide gel. Among the 24 fractions collected,
proteins were visible in fractions 2–15. (B) Transfection efficiency of nanopar-
ticles formulated using the clinical protamine (‘clinical’ ) or each Sephadex frac-
tion mixed with mRNA. HEK cells were incubated with nanoparticles (0.5 mg of
mRNA and 1.5mg of protamine) formed from the fractions (90mg/ml) mixed
with mRNA (30mg/ml). After 18 h of incubation, the luminescence was meas-
ured. Data represent triplicate mean values; error bars: SD.
Figure 3. Immunostimulatory features of various types of proticles. Human
PBMCs were cultivated for 24 h in the presence of either proticles (‘protamine-
mRNA NPs,’ 1 mg of mRNA, and 3mg of protamine per well) or protamine alone
(3mg per well). Supernatants were analyzed by ELISA for their IFN-a content.
Data represent triplicate mean values; error bars: SD.
Figure 4. Transfection capacity in HEK cells. A total of 105 cells per well were
incubated for 20 hours with proticles (1mg of RNA and 3 mg of protamine per
well). Then, the relative amounts of luciferase produced were evaluated by the
addition of luciferin and the measurement of light emission in a luminometer.
Data represent triplicate mean values; error bars: SD. A t-test analysis shows
that ‘clinical’ protamine is significantly better than all other protamines with
p <.0001.
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In summary, we show that various commercially available
protamines differ in their appearance on SDS-PAGE and in
capacity to effectively transfect mRNA into the cytosol.
However, all tested protamines were equivalent in their abil-
ity to form nanoparticles when mixed with RNA and to
deliver RNA to endosome resident TLRs. Protamines are fre-
quently used to package nucleic acids (antisense, siRNA,
immunostimulatory nucleic acids, plasmid DNA, or messen-
ger RNA) (Hoerr et al., 2000; Scheel et al., 2005; Vighi et al.,
2012; Weide et al., 2009; Feyerabend et al., 2009), and several
such formulations are in clinical trials. Our work highlights
the functional relevance of the protamine source in the
development of pharmaceutical drugs and paves the way
toward the development of standardized and optimized pro-
tocols for the delivery of nucleic acids.
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